Catherine Jankowski
Concepts (336)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 35 | 2024 | 2045 | 4.900 |
Why?
| | HIV Infections | 36 | 2025 | 2820 | 4.080 |
Why?
| | Frailty | 7 | 2024 | 170 | 2.150 |
Why?
| | Body Composition | 15 | 2024 | 678 | 1.630 |
Why?
| | Caregivers | 4 | 2024 | 876 | 1.430 |
Why?
| | Motivation | 6 | 2024 | 568 | 1.400 |
Why?
| | Dehydroepiandrosterone | 3 | 2018 | 51 | 1.210 |
Why?
| | Neoplasms | 7 | 2023 | 2661 | 1.200 |
Why?
| | Bone Density | 8 | 2021 | 487 | 1.190 |
Why?
| | Aging | 12 | 2024 | 1864 | 1.180 |
Why?
| | Quality of Life | 11 | 2025 | 2885 | 1.110 |
Why?
| | Exercise Therapy | 7 | 2024 | 437 | 0.940 |
Why?
| | Aged | 41 | 2024 | 23851 | 0.930 |
Why?
| | Integrative Medicine | 1 | 2025 | 14 | 0.920 |
Why?
| | Drama | 1 | 2024 | 5 | 0.890 |
Why?
| | Muscle, Skeletal | 7 | 2023 | 1709 | 0.880 |
Why?
| | Complementary Therapies | 1 | 2025 | 91 | 0.860 |
Why?
| | Self-Management | 1 | 2025 | 166 | 0.800 |
Why?
| | Independent Living | 1 | 2024 | 105 | 0.790 |
Why?
| | Collagen Type I | 3 | 2021 | 133 | 0.790 |
Why?
| | Alkaline Phosphatase | 2 | 2021 | 148 | 0.770 |
Why?
| | Ibuprofen | 2 | 2021 | 84 | 0.770 |
Why?
| | Muscle Strength | 3 | 2024 | 317 | 0.760 |
Why?
| | Art Therapy | 1 | 2022 | 20 | 0.750 |
Why?
| | Middle Aged | 44 | 2025 | 33310 | 0.730 |
Why?
| | Health Education | 1 | 2024 | 338 | 0.700 |
Why?
| | Poverty | 1 | 2024 | 521 | 0.690 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 85 | 0.680 |
Why?
| | Humans | 83 | 2025 | 137294 | 0.680 |
Why?
| | HIV Long-Term Survivors | 1 | 2020 | 3 | 0.660 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 116 | 0.660 |
Why?
| | Interleukin-6 | 2 | 2021 | 778 | 0.650 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 350 | 0.640 |
Why?
| | Interleukin-10 | 1 | 2021 | 302 | 0.610 |
Why?
| | Critical Illness | 1 | 2025 | 808 | 0.600 |
Why?
| | Attitude to Health | 2 | 2019 | 440 | 0.600 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 53 | 0.580 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 218 | 0.570 |
Why?
| | Preventive Health Services | 1 | 2020 | 148 | 0.570 |
Why?
| | Anti-HIV Agents | 7 | 2020 | 772 | 0.560 |
Why?
| | Frail Elderly | 6 | 2024 | 132 | 0.560 |
Why?
| | Female | 54 | 2025 | 73052 | 0.550 |
Why?
| | Peptides | 3 | 2021 | 982 | 0.550 |
Why?
| | Adiposity | 3 | 2013 | 518 | 0.530 |
Why?
| | Male | 43 | 2025 | 67560 | 0.530 |
Why?
| | Perception | 1 | 2019 | 361 | 0.500 |
Why?
| | Resistance Training | 2 | 2024 | 164 | 0.500 |
Why?
| | Adaptation, Physiological | 3 | 2021 | 549 | 0.500 |
Why?
| | Hormone Replacement Therapy | 3 | 2018 | 96 | 0.480 |
Why?
| | Dehydroepiandrosterone Sulfate | 3 | 2013 | 46 | 0.460 |
Why?
| | Cross-Sectional Studies | 13 | 2024 | 5436 | 0.460 |
Why?
| | Guidelines as Topic | 2 | 2019 | 278 | 0.450 |
Why?
| | Estrogens | 4 | 2013 | 368 | 0.450 |
Why?
| | Fatigue | 5 | 2022 | 328 | 0.440 |
Why?
| | Telemedicine | 1 | 2023 | 854 | 0.440 |
Why?
| | Self Efficacy | 4 | 2024 | 395 | 0.420 |
Why?
| | Sex Factors | 2 | 2018 | 2073 | 0.410 |
Why?
| | Heart Failure | 2 | 2023 | 2234 | 0.400 |
Why?
| | Qualitative Research | 6 | 2024 | 1367 | 0.370 |
Why?
| | Nausea | 2 | 2023 | 112 | 0.370 |
Why?
| | Survivors | 2 | 2014 | 488 | 0.370 |
Why?
| | Inflammation | 3 | 2021 | 2836 | 0.360 |
Why?
| | Bone and Bones | 2 | 2013 | 316 | 0.340 |
Why?
| | Physical Fitness | 4 | 2017 | 209 | 0.340 |
Why?
| | Interviews as Topic | 3 | 2024 | 770 | 0.330 |
Why?
| | Acetaminophen | 1 | 2012 | 268 | 0.320 |
Why?
| | Health Status | 2 | 2020 | 789 | 0.310 |
Why?
| | Postmenopause | 5 | 2019 | 365 | 0.310 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2113 | 0.310 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 1242 | 0.290 |
Why?
| | HIV-1 | 5 | 2020 | 861 | 0.290 |
Why?
| | Adult | 21 | 2025 | 37724 | 0.280 |
Why?
| | Sarcopenia | 2 | 2023 | 82 | 0.280 |
Why?
| | Healthy Aging | 2 | 2024 | 35 | 0.280 |
Why?
| | Menopause | 2 | 2021 | 319 | 0.270 |
Why?
| | Accelerometry | 2 | 2019 | 99 | 0.260 |
Why?
| | Pain | 2 | 2023 | 759 | 0.260 |
Why?
| | Adolescent | 10 | 2025 | 21499 | 0.260 |
Why?
| | Child, Preschool | 7 | 2025 | 11080 | 0.260 |
Why?
| | Focus Groups | 3 | 2025 | 515 | 0.260 |
Why?
| | Glucose | 1 | 2011 | 1028 | 0.250 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 20 | 0.240 |
Why?
| | Motor Activity | 3 | 2014 | 719 | 0.240 |
Why?
| | Weight Loss | 4 | 2020 | 779 | 0.230 |
Why?
| | Cancer Survivors | 2 | 2021 | 282 | 0.230 |
Why?
| | Radioisotope Dilution Technique | 1 | 2004 | 14 | 0.230 |
Why?
| | Biomarkers | 6 | 2021 | 4164 | 0.230 |
Why?
| | Body Water | 1 | 2004 | 21 | 0.230 |
Why?
| | Missouri | 1 | 2024 | 61 | 0.220 |
Why?
| | Urine | 1 | 2004 | 56 | 0.220 |
Why?
| | Social Stigma | 2 | 2023 | 135 | 0.220 |
Why?
| | Serum | 1 | 2004 | 59 | 0.220 |
Why?
| | Chile | 1 | 2024 | 24 | 0.220 |
Why?
| | Absorptiometry, Photon | 4 | 2021 | 254 | 0.220 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2004 | 33 | 0.220 |
Why?
| | Deuterium | 1 | 2004 | 99 | 0.220 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 55 | 0.210 |
Why?
| | Feasibility Studies | 2 | 2025 | 949 | 0.210 |
Why?
| | Lumbar Vertebrae | 3 | 2018 | 246 | 0.200 |
Why?
| | Intention | 1 | 2024 | 170 | 0.200 |
Why?
| | Parents | 2 | 2022 | 1357 | 0.200 |
Why?
| | Heart Rate | 2 | 2024 | 823 | 0.200 |
Why?
| | Saliva | 1 | 2004 | 244 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 658 | 0.200 |
Why?
| | Autophagy | 1 | 2025 | 281 | 0.200 |
Why?
| | Surveys and Questionnaires | 9 | 2024 | 5769 | 0.200 |
Why?
| | Child | 8 | 2025 | 21999 | 0.190 |
Why?
| | Proxy | 1 | 2022 | 29 | 0.190 |
Why?
| | High-Intensity Interval Training | 1 | 2022 | 25 | 0.190 |
Why?
| | Malnutrition | 1 | 2023 | 82 | 0.190 |
Why?
| | Aged, 80 and over | 8 | 2021 | 7607 | 0.190 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 10 | 0.190 |
Why?
| | Symptom Assessment | 1 | 2023 | 128 | 0.180 |
Why?
| | Femur | 2 | 2018 | 258 | 0.180 |
Why?
| | Blood Platelets | 1 | 2025 | 407 | 0.180 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 43 | 0.180 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 60 | 0.180 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 42 | 0.180 |
Why?
| | Attitude | 1 | 2023 | 260 | 0.180 |
Why?
| | Residence Characteristics | 1 | 2024 | 356 | 0.180 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 87 | 0.180 |
Why?
| | Prospective Studies | 3 | 2023 | 7595 | 0.170 |
Why?
| | Advance Directives | 1 | 2021 | 70 | 0.170 |
Why?
| | Raloxifene Hydrochloride | 2 | 2013 | 15 | 0.160 |
Why?
| | Viral Load | 2 | 2020 | 464 | 0.160 |
Why?
| | Protective Factors | 1 | 2020 | 93 | 0.160 |
Why?
| | Perimenopause | 1 | 2020 | 63 | 0.160 |
Why?
| | Life Expectancy | 1 | 2020 | 68 | 0.160 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 346 | 0.150 |
Why?
| | Health Behavior | 1 | 2024 | 757 | 0.150 |
Why?
| | Cell Phone | 1 | 2020 | 75 | 0.150 |
Why?
| | Placebos | 2 | 2011 | 199 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 659 | 0.150 |
Why?
| | DNA Methylation | 1 | 2023 | 644 | 0.150 |
Why?
| | Blood Glucose | 4 | 2013 | 2182 | 0.150 |
Why?
| | Mexican Americans | 1 | 1999 | 120 | 0.140 |
Why?
| | Housing | 1 | 2019 | 150 | 0.140 |
Why?
| | United States | 4 | 2024 | 14742 | 0.140 |
Why?
| | Advance Care Planning | 1 | 2021 | 206 | 0.140 |
Why?
| | Chronic Disease | 2 | 2021 | 1788 | 0.140 |
Why?
| | Muscle Proteins | 1 | 2019 | 229 | 0.140 |
Why?
| | Insulin | 5 | 2013 | 2406 | 0.140 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 284 | 0.130 |
Why?
| | Self Care | 1 | 2020 | 375 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1464 | 0.130 |
Why?
| | Dietary Proteins | 2 | 2015 | 135 | 0.130 |
Why?
| | Obesity | 3 | 2016 | 2983 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 370 | 0.130 |
Why?
| | Colorado | 2 | 2024 | 4527 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2018 | 162 | 0.120 |
Why?
| | Physical Therapists | 1 | 2017 | 62 | 0.120 |
Why?
| | Risk Factors | 7 | 2020 | 10368 | 0.120 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2016 | 115 | 0.120 |
Why?
| | Estradiol | 1 | 2019 | 518 | 0.120 |
Why?
| | Anxiety | 1 | 2023 | 1036 | 0.120 |
Why?
| | Caseins | 1 | 2015 | 20 | 0.120 |
Why?
| | Phenylketonurias | 1 | 2015 | 15 | 0.120 |
Why?
| | Adaptation, Psychological | 2 | 2020 | 655 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 268 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2020 | 1101 | 0.110 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 29 | 0.110 |
Why?
| | Diet, Protein-Restricted | 1 | 2013 | 11 | 0.110 |
Why?
| | Hospitalization | 1 | 2024 | 2214 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 309 | 0.100 |
Why?
| | Pyridoxine | 1 | 2013 | 36 | 0.100 |
Why?
| | Neoadjuvant Therapy | 1 | 2016 | 403 | 0.100 |
Why?
| | Decision Making | 1 | 2021 | 898 | 0.100 |
Why?
| | Developmental Disabilities | 1 | 2016 | 265 | 0.100 |
Why?
| | Sleep | 1 | 2020 | 755 | 0.100 |
Why?
| | Dietary Supplements | 2 | 2015 | 562 | 0.100 |
Why?
| | Activities of Daily Living | 1 | 2017 | 415 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 698 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 232 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2025 | 10800 | 0.100 |
Why?
| | Microbiota | 1 | 2021 | 761 | 0.100 |
Why?
| | Risk Assessment | 2 | 2020 | 3439 | 0.100 |
Why?
| | Homocystinuria | 1 | 2013 | 71 | 0.100 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 146 | 0.100 |
Why?
| | Thigh | 2 | 2010 | 49 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2008 | 1985 | 0.100 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2012 | 23 | 0.100 |
Why?
| | Young Adult | 3 | 2025 | 13163 | 0.100 |
Why?
| | Depression | 2 | 2019 | 1408 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 252 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 128 | 0.090 |
Why?
| | Public Health | 1 | 2017 | 579 | 0.090 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2011 | 41 | 0.090 |
Why?
| | Amino Acids | 1 | 2015 | 501 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4026 | 0.090 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 232 | 0.090 |
Why?
| | Sports | 1 | 1994 | 231 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2015 | 707 | 0.090 |
Why?
| | Osteogenesis | 1 | 2012 | 187 | 0.090 |
Why?
| | Cholesterol, HDL | 1 | 2011 | 203 | 0.090 |
Why?
| | Lipids | 2 | 2013 | 666 | 0.090 |
Why?
| | Hip | 2 | 2011 | 55 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2013 | 316 | 0.080 |
Why?
| | Osteoporosis | 1 | 2013 | 243 | 0.080 |
Why?
| | Accidental Falls | 1 | 2012 | 194 | 0.080 |
Why?
| | Subcutaneous Fat | 1 | 2010 | 81 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 91 | 0.080 |
Why?
| | Cholesterol | 1 | 2011 | 410 | 0.080 |
Why?
| | Cholesterol, LDL | 1 | 2011 | 366 | 0.080 |
Why?
| | Triglycerides | 1 | 2011 | 524 | 0.080 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 244 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2013 | 515 | 0.080 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2008 | 59 | 0.070 |
Why?
| | Dyslipidemias | 1 | 2010 | 176 | 0.070 |
Why?
| | Geriatric Assessment | 2 | 2023 | 224 | 0.070 |
Why?
| | Linear Models | 2 | 2008 | 846 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2013 | 3546 | 0.070 |
Why?
| | Area Under Curve | 2 | 2010 | 315 | 0.070 |
Why?
| | Weight Gain | 1 | 2011 | 519 | 0.070 |
Why?
| | Vascular Stiffness | 1 | 2012 | 493 | 0.070 |
Why?
| | Diet | 2 | 2006 | 1275 | 0.070 |
Why?
| | Body Mass Index | 3 | 2013 | 2373 | 0.070 |
Why?
| | Calcium, Dietary | 1 | 2006 | 57 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1456 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 1028 | 0.060 |
Why?
| | Cognition | 1 | 2013 | 1169 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 1999 | 2516 | 0.060 |
Why?
| | Testosterone | 1 | 2008 | 401 | 0.060 |
Why?
| | Energy Metabolism | 3 | 2013 | 920 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2243 | 0.050 |
Why?
| | Florida | 1 | 2023 | 103 | 0.050 |
Why?
| | Rest | 1 | 2004 | 121 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2850 | 0.050 |
Why?
| | Europe | 2 | 2015 | 414 | 0.050 |
Why?
| | C-Peptide | 1 | 2004 | 163 | 0.050 |
Why?
| | Social Support | 2 | 2018 | 619 | 0.050 |
Why?
| | Vitamin D | 1 | 2006 | 397 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 268 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2004 | 364 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2032 | 0.050 |
Why?
| | Habits | 1 | 2022 | 49 | 0.050 |
Why?
| | Time Factors | 4 | 2019 | 6818 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2010 | 1203 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1321 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2006 | 765 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2005 | 630 | 0.040 |
Why?
| | Actigraphy | 1 | 2020 | 110 | 0.040 |
Why?
| | Death | 1 | 2021 | 118 | 0.040 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2000 | 113 | 0.040 |
Why?
| | Meiosis | 1 | 2000 | 81 | 0.040 |
Why?
| | Comorbidity | 1 | 2024 | 1624 | 0.040 |
Why?
| | Premenopause | 1 | 2020 | 131 | 0.040 |
Why?
| | DNA Transposable Elements | 1 | 2000 | 123 | 0.040 |
Why?
| | Family | 1 | 2023 | 666 | 0.040 |
Why?
| | Postprandial Period | 1 | 1999 | 107 | 0.040 |
Why?
| | Mitochondria | 1 | 2025 | 947 | 0.040 |
Why?
| | Counseling | 1 | 2021 | 393 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2025 | 3009 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 145 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1128 | 0.030 |
Why?
| | DNA Damage | 1 | 2000 | 422 | 0.030 |
Why?
| | Affect | 1 | 2020 | 293 | 0.030 |
Why?
| | Axilla | 1 | 2016 | 47 | 0.030 |
Why?
| | Health Services for the Aged | 1 | 2017 | 80 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 404 | 0.030 |
Why?
| | Sentinel Lymph Node | 1 | 2016 | 45 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 2000 | 558 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 21 | 0.030 |
Why?
| | Infant | 3 | 2015 | 9451 | 0.030 |
Why?
| | Turkey | 1 | 2015 | 22 | 0.030 |
Why?
| | Professional Role | 1 | 2017 | 165 | 0.030 |
Why?
| | Smartphone | 1 | 2016 | 92 | 0.030 |
Why?
| | Liver | 1 | 2004 | 1941 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2016 | 170 | 0.030 |
Why?
| | Phenylalanine | 1 | 2015 | 68 | 0.030 |
Why?
| | World Health Organization | 1 | 2015 | 123 | 0.030 |
Why?
| | Tracheostomy | 1 | 2016 | 132 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1623 | 0.030 |
Why?
| | Body Constitution | 1 | 1994 | 55 | 0.030 |
Why?
| | Aging, Premature | 1 | 2013 | 13 | 0.030 |
Why?
| | Betaine | 1 | 2013 | 74 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 39 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 38 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 49 | 0.030 |
Why?
| | Homocysteine | 1 | 2013 | 156 | 0.030 |
Why?
| | Methionine | 1 | 2013 | 160 | 0.020 |
Why?
| | Amino Acids, Essential | 1 | 2012 | 13 | 0.020 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2012 | 36 | 0.020 |
Why?
| | Dietetics | 1 | 2012 | 27 | 0.020 |
Why?
| | Nutritional Support | 1 | 2012 | 34 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2016 | 1374 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 325 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2015 | 6054 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 152 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2016 | 643 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 270 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3568 | 0.020 |
Why?
| | United Kingdom | 1 | 2012 | 315 | 0.020 |
Why?
| | Bone Remodeling | 1 | 2011 | 75 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 209 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 500 | 0.020 |
Why?
| | Weight Reduction Programs | 1 | 2011 | 116 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 201 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5726 | 0.020 |
Why?
| | Contraceptive Agents | 1 | 2010 | 68 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2608 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2012 | 696 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1150 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 725 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 752 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1055 | 0.020 |
Why?
| | Executive Function | 1 | 2013 | 448 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 1172 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 786 | 0.020 |
Why?
| | Mice | 1 | 2025 | 17774 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1095 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 916 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 577 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 2808 | 0.020 |
Why?
| | Buttocks | 1 | 2005 | 14 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2135 | 0.010 |
Why?
| | Abdomen | 1 | 2005 | 125 | 0.010 |
Why?
| | Animals | 1 | 2025 | 36862 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 5125 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 15639 | 0.010 |
Why?
| | Gene Conversion | 1 | 2000 | 7 | 0.010 |
Why?
| | Aminohydrolases | 1 | 2000 | 4 | 0.010 |
Why?
| | MutS Homolog 2 Protein | 1 | 2000 | 15 | 0.010 |
Why?
| | Genes, Fungal | 1 | 2000 | 53 | 0.010 |
Why?
| | Endonucleases | 1 | 2000 | 32 | 0.010 |
Why?
| | DNA Repair Enzymes | 1 | 2000 | 28 | 0.010 |
Why?
| | Pyrophosphatases | 1 | 2000 | 28 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2679 | 0.010 |
Why?
| | Alcohol Oxidoreductases | 1 | 2000 | 62 | 0.010 |
Why?
| | Fungal Proteins | 1 | 2000 | 134 | 0.010 |
Why?
| | Alleles | 1 | 2000 | 892 | 0.010 |
Why?
| | Base Sequence | 1 | 2000 | 2182 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2000 | 2904 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2000 | 1250 | 0.010 |
Why?
| | Eating | 1 | 1995 | 379 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2000 | 1501 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1720 | 0.010 |
Why?
|
|
Jankowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|